Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy
Crossref DOI link:
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Carlos, Cueva Jumbo Juan
Hammock, Bruce D.
Text and Data Mining valid from 2021-02-25
Version of Record valid from 2021-02-25
14 March 2020
9 November 2020
24 December 2020
25 February 2021
The authors declare no competing interests.